Analyst Expectations For Charles River's Future
Throughout the last three months, 8 analysts have evaluated Charles River (NYSE:CRL), offering a diverse set of opinions from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 1 | 4 | 3 | 0 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 0 | 2 | 0 | 0 | 0 |
| 2M Ago | 1 | 1 | 0 | 0 | 0 |
| 3M Ago | 0 | 1 | 2 | 0 | 0 |
In the assessment of 12-month price targets, analysts unveil insights for Charles River, presenting an average target of $213.12, a high estimate of $265.00, and a low estimate of $175.00. This current average reflects an increase of 0.95% from the previous average price target of $211.12.
Understanding Analyst Ratings: A Comprehensive Breakdown
The analysis of recent analyst actions sheds light on the perception of Charles River by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Ann Hynes | Mizuho | Lowers | Neutral | $175.00 | $215.00 |
| Luke Sergott | Barclays | Lowers | Overweight | $200.00 | $215.00 |
| Ross Muken | Evercore ISI Group | Lowers | Outperform | $200.00 | $260.00 |
| Patrick Donnelly | Citigroup | Raises | Buy | $265.00 | $200.00 |
| Ross Muken | Evercore ISI Group | Raises | Outperform | $260.00 | $250.00 |
| Ann Hynes | Mizuho | Raises | Neutral | $200.00 | $174.00 |
| Luke Sergott | Barclays | Raises | Overweight | $215.00 | $210.00 |
| Casey Woodring | JP Morgan | Raises | Neutral | $190.00 | $165.00 |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Charles River. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Charles River compared to the broader market.
- Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Charles River's stock. This examination reveals shifts in analysts' expectations over time.
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Charles River's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
Stay up to date on Charles River analyst ratings.
Get to Know Charles River Better
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Charles River's Financial Performance
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Negative Revenue Trend: Examining Charles River's financials over 3M reveals challenges. As of 30 September, 2025, the company experienced a decline of approximately -0.49% in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Charles River's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 5.42%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Charles River's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 1.61%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Charles River's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 0.72%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Charles River's debt-to-equity ratio stands notably higher than the industry average, reaching 0.77. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
The Basics of Analyst Ratings
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.